Stewart BW, Kleihues P. World Cancer Report 2003. Geneva: World Health Organization Press.
Boyle P, Levin B. World Cancer Report 2008. Geneva: World Health Organization Press.
Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society; 2013.
Peer, D, Karp, JM, Hong, S, Farokhzad, OC, Margalit, R, Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751–760.
Haley, B, Frenkel, E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008, 26:57–64.
Hans, ML, Lowman, AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002, 6:319–327.
Kumari, A, Yadav, SK, Yadav, SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010, 75:1–18.
Mahapatro, A, Singh, DK. Biodegradable nanoparticles are excellent vehicle for site directed in‐vivo delivery of drugs and vaccines. J Nanobiotechnol 2011, 9:55.
Soppimath, KS, Aminabhavi, TM, Kulkarni, AR, Rudzinski, WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001, 70:1–20.
Rao, JP, Geckeler, KE. Polymer nanoparticles: preparation techniques and size‐control parameters. Prog Polym Sci 2011, 36:887–913.
McNeil, SE. Characterization of nanoparticles intended for drug delivery. Methods Mol Biol 2011, 697:269.
Averineni, RK, Shavi, GV, Gurram, AK, Deshpande, PB, Arumugam, K, Maliyakkal, N, Meka, SR, Nayanabhirama, U. PLGA 50:50 nanoparticles of paclitaxel: development, in vitro anti‐tumor activity in BT‐549 cells and in vivo evaluation. Bull Mater Sci 2012, 35:319–326.
Chan, JM, Valencia, PM, Zhang, L, Langer, R, Farokhzad, OC. Polymeric nanoparticles for drug delivery. Methods Mol Biol 2010, 624:163–175.
Chen, KJ, Tang, L, Garcia, MA, Wang, H, Lu, H, Lin, WY, Hou, S, Yin, Q, Shen, CK, Cheng, J, et al. The therapeutic efficacy of camptothecin‐encapsulated supramolecular nanoparticles. Biomaterials 2012, 33:1162–1169.
Liu, Y, Zhang, N. Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging. Biomaterials 2012, 33:5363–5375.
Danhier, F, Lecouturier, N, Vroman, B, Jerome, C, Marchand‐Brynaert, J, Feron, O, Preat, V. Paclitaxel‐loaded PEGylated PLGA‐based nanoparticles: in vitro and in vivo evaluation. J Control Release 2009, 133:11–17.
Cheng, J, Teply, BA, Sherifi, I, Sung, J, Luther, G, Gu, FX, Levy‐Nissenbaum, E, Radovic‐Moreno, AF, Langer, R, Farokhzad, OC. Formulation of functionalized PLGA‐PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28:869–876.
Farokhzad, OC, Cheng, J, Teply, BA, Sherifi, I, Jon, S, Kantoff, PW, Richie, JP, Langer, R. Targeted nanoparticle‐aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006, 103:6315–6320.
Hrkach, J, Von Hoff, D, Mukkaram Ali, M, Andrianova, E, Auer, J, Campbell, T, De Witt, D, Figa, M, Figueiredo, M, Horhota, A, et al. Preclinical development and clinical translation of a PSMA‐targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128ra139.
Gryparis, EC, Hatziapostolou, M, Papadimitriou, E, Avgoustakis, K. Anticancer activity of cisplatin‐loaded PLGA‐mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm 2007, 67:1–8.
Cheng, L, Jin, C, Lv, W, Ding, Q, Han, X. Developing a highly stable PLGA‐mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PLoS One 2011, 6:e25433.
Dhar, S, Gu, FX, Langer, R, Farokhzad, OC, Lippard, SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug‐PLGA‐PEG nanoparticles. Proc Natl Acad Sci U S A 2008, 105:17356–17361.
Dhar, S, Kolishetti, N, Lippard, SJ, Farokhzad, OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A 2011, 108:1850–1855.
Graf, N, Bielenberg, DR, Kolishetti, N, Muus, C, Banyard, J, Farokhzad, OC, Lippard, SJ. α(V)β(3) integrin‐targeted PLGA‐PEG nanoparticles for enhanced anti‐tumor efficacy of a Pt(IV) prodrug. ACS Nano 2012, 6:4530–4539.
Moreno, D, Zalba, S, Navarro, I, Tros de Ilarduya, C, Garrido, MJ. Pharmacodynamics of cisplatin‐loaded PLGA nanoparticles administered to tumor‐bearing mice. Eur J Pharm Biopharm 2010, 74:265–274.
Moreno, D, de Ilarduya, CT, Bandres, E, Bunuales, M, Azcona, M, Garcia‐Foncillas, J, Garrido, MJ. Characterization of cisplatin cytotoxicity delivered from PLGA‐systems. Eur J Pharm Biopharm 2008, 68:503–512.
Nair, KL, Jagadeeshan, S, Nair, SA, Kumar, GS. Biological evaluation of 5‐fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomed 2011, 6:1685–1697.
Cheng, MR, Li, Q, Wan, T, He, B, Han, J, Chen, HX, Yang, FX, Wang, W, Xu, HZ, Ye, T, et al. Galactosylated chitosan/5‐fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects. World J Gastroenterol 2012, 18:6076–6087.
Cheng, M, He, B, Wan, T, Zhu, W, Han, J, Zha, B, Chen, H, Yang, F, Li, Q, Wang, W, et al. 5‐Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One 2012, 7:e47115.
Yadav, AK, Agarwal, A, Rai, G, Mishra, P, Jain, S, Mishra, AK, Agrawal, H, Agrawal, GP. Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5‐fluorouracil. Drug Deliv 2010, 17:561–572.
Li, S, Wang, A, Jiang, W, Guan, Z. Pharmacokinetic characteristics and anticancer effects of 5‐fluorouracil loaded nanoparticles. BMC Cancer 2008, 8:103.
Betancourt, T, Brown, B, Brannon‐Peppas, L. Doxorubicin‐loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine 2007, 2:219–232.
Chang, L, Deng, L, Wang, W, Lv, Z, Hu, F, Dong, A, Zhang, J. Poly(ethyleneglycol)‐b‐poly(ε‐caprolactone‐co‐γ‐hydroxyl‐ε‐caprolactone) bearing pendant hydroxyl groups as nanocarriers for doxorubicin delivery. Biomacromolecules 2012, 13:3301–3310.
Wohlfart, S, Khalansky, AS, Gelperina, S, Maksimenko, O, Bernreuther, C, Glatzel, M, Kreuter, J. Efficient chemotherapy of rat glioblastoma using doxorubicin‐loaded PLGA nanoparticles with different stabilizers. PLoS One 2011, 6:e19121.
Chittasupho, C, Xie, SX, Baoum, A, Yakovleva, T, Siahaan, TJ, Berkland, CJ. ICAM‐1 targeting of doxorubicin‐loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci 2009, 37:141–150.
Park, H, Yang, J, Lee, J, Haam, S, Choi, IH, Yoo, KH. Multifunctional nanoparticles for combined doxorubicin and photothermal treatments. ACS Nano 2009, 3:2919–2926.
Amjadi, I, Rabiee, M, Hosseini, MS, Mozafari, M. Synthesis and characterization of doxorubicin‐loaded poly(lactide‐co‐glycolide) nanoparticles as a sustained‐release anticancer drug delivery system. Appl Biochem Biotechnol 2012, 168:1434–1447.
Liu, CW, Lin, WJ. Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor‐active targeting ligand for doxorubicin. Int J Nanomed 2012, 7:4749–4767.
Perez, E, Benito, M, Teijon, C, Olmo, R, Teijon, JM, Blanco, MD. Tamoxifen‐loaded nanoparticles based on a novel mixture of biodegradable polyesters: characterization and in vitro evaluation as sustained release systems. J Microencapsul 2012, 29:309–322.
Cavalli, R, Bisazza, A, Bussano, R, Trotta, M, Civra, A, Lembo, D, Ranucci, E, Ferruti, P. Poly(amidoamine)‐cholesterol conjugate nanoparticles obtained by electrospraying as novel tamoxifen delivery system. J Drug Deliv 2011, 2011:587604.
Jain, AK, Swarnakar, NK, Godugu, C, Singh, RP, Jain, S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 2011, 32:503–515.
Renoir, JM, Stella, B, Ameller, T, Connault, E, Opolon, P, Marsaud, V. Improved anti‐tumoral capacity of mixed and pure anti‐oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems. J Steroid Biochem Mol Biol 2006, 102:114–127.
Devalapally, H, Duan, Z, Seiden, MV, Amiji, MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen‐loaded biodegradable polymeric nanoparticles. Clin Cancer Res 2008, 14:3193–3203.
Arya, G, Vandana, M, Acharya, S, Sahoo, SK. Enhanced antiproliferative activity of Herceptin (HER2)‐conjugated gemcitabine‐loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomed Nanotechnol Biol Med 2011, 7:859–870.
Arias, JL, Reddy, LH, Couvreur, P. Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system. Biomacromolecules 2011, 12:97–104.
Aggarwal, S, Yadav, S, Gupta, S. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer. J Biomed Nanotechnol 2011, 7:137–138.
Papa, AL, Basu, S, Sengupta, P, Banerjee, D, Sengupta, S, Harfouche, R. Mechanistic studies of Gemcitabine‐loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer 2012, 12:419.
Jia, L, Zheng, JJ, Jiang, SM, Huang, KH. Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine‐loaded PEG‐PDLLA nanovesicles. World J Gastroenterol 2010, 16:1008–1013.
Hou, Z, Zhan, C, Jiang, Q, Hu, Q, Li, L, Chang, D, Yang, X, Wang, Y, Li, Y, Ye, S, et al. Both FA‐ and mPEG‐conjugated chitosan nanoparticles for targeted cellular uptake and enhanced tumor tissue distribution. Nanoscale Res Lett 2011, 6:563.
Yordanov, G, Skrobanska, R, Evangelatov, A. Entrapment of epirubicin in poly(butyl cyanoacrylate) colloidal nanospheres by nanoprecipitation: formulation development and in vitro studies on cancer cell lines. Colloids Surf B Biointerfaces 2012, 92:98–105.
Zhang, HZ, Li, XM, Gao, FP, Liu, LR, Zhou, ZM, Zhang, QQ. Preparation of folate‐modified pullulan acetate nanoparticles for tumor‐targeted drug delivery. Drug Deliv 2010, 17:48–57.
Yallapu, MM, Dobberpuhl, MR, Maher, DM, Jaggi, M, Chauhan, SC. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab 2012, 13:120–128.
Mukerjee, A, Vishwanatha, JK. Formulation, characterization and evaluation of curcumin‐loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009, 29:3867–3875.
Gryparis, EC, Mattheolabakis, G, Bikiaris, D, Avgoustakis, K. Effect of conditions of preparation on the size and encapsulation properties of PLGA‐mPEG nanoparticles of cisplatin. Drug Deliv 2007, 14:371–380.
Danhier, F, Ansorena, E, Silva, JM, Coco, R, Le Breton, A, Preat, V. PLGA‐based nanoparticles: an overview of biomedical applications. J Control Release 2012, 161:505–522.
Wolf, DM, Langan‐Fahey, SM, Parker, CJ, McCague, R, Jordan, VC. Investigation of the mechanism of tamoxifen‐stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 1993, 85:806–812.
Erdogar, N, Iskit, AB, Mungan, NA, Bilensoy, E. Prolonged retention and in vivo evaluation of cationic nanoparticles loaded with Mitomycin C designed for intravesical chemotherapy of bladder tumours. J Microencapsul 2012, 29:576–582.
Erdogar, N, Mungan, A, Bilensoy, E. Preparation and characterization of cationic nanoparticles loaded with Mitomycin C by double emulsion and ionotropic gelation techniques. J Control Release 2010, 148:e78–e79.
Khalil, NM, do Nascimento, TC, Casa, DM, Dalmolin, LF, de Mattos, AC, Hoss, I, Romano, MA, Mainardes, RM. Pharmacokinetics of curcumin‐loaded PLGA and PLGA‐PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 2013, 101:353–360.
Ghildiyal, M, Zamore, PD. Small silencing RNAs: an expanding universe. Nat Rev Genet 2009, 10:94–108.
Tokatlian, T, Segura, T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2:305–315.
Ozpolat, B, Sood, AK, Lopez‐Berestein, G. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 2010, 267:44–53.
Bartel, DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215–233.
Bartel, DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281–297.
Bhardwaj, A, Singh, S, Singh, AP. MicroRNA‐based cancer therapeutics: big hope from small RNAs. Mol Cell Pharmacol 2010, 2:213–219.
Cimmino, A, Calin, GA, Fabbri, M, Iorio, MV, Ferracin, M, Shimizu, M, Wojcik, SE, Aqeilan, RI, Zupo, S, Dono, M, et al. miR‐15 and miR‐16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005, 102:13944–13949.
Hammond, SM. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006, 16:4–9.
Hamilton, AJ, Baulcombe, DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999, 286:950–952.
Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K, Tuschl, T. Duplexes of 21‐nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494–498.
Hammond, SM, Bernstein, E, Beach, D, Hannon, GJ. An RNA‐directed nuclease mediates post‐transcriptional gene silencing in Drosophila cells. Nature 2000, 404:293–296.
Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE, Mello, CC. Potent and specific genetic interference by double‐stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806–811.
Babar, IA, Cheng, CJ, Booth, CJ, Liang, X, Weidhaas, JB, Saltzman, WM, Slack, FJ. Nanoparticle‐based therapy in an in vivo microRNA‐155 (miR‐155)‐dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 2012, 109:E1695–E1704.
Jin, H, Yu, Y, Chrisler, WB, Xiong, Y, Hu, D, Lei, C. Delivery of microRNA‐10b with polylysine nanoparticles for inhibition of breast cancer cell wound healing. Breast Cancer 2012, 6:9–19.
Ren, Y, Kang, CS, Yuan, XB, Zhou, X, Xu, P, Han, L, Wang, GX, Jia, Z, Zhong, Y, Yu, S, et al. Co‐delivery of as‐miR‐21 and 5‐FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 2010, 21:303–314.
Liang, GF, Zhu, YL, Sun, B, Hu, FH, Tian, T, Li, SC, Xiao, ZD. PLGA‐based gene delivering nanoparticle enhance suppression effect of miRNA in HePG2 cells. Nanoscale Res Lett 2011, 6:447.
Cheng, CJ, Saltzman, WM. Polymer nanoparticle‐mediated delivery of microRNA inhibition and alternative splicing. Mol Pharm 2012, 9:1481–1488.
Liu, XQ, Song, WJ, Sun, TM, Zhang, PZ, Wang, J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD‐functionalized nanoparticles. Mol Pharm 2011, 8:250–259.
Krutzfeldt, J, Rajewsky, N, Braich, R, Rajeev, KG, Tuschl, T, Manoharan, M, Stoffel, M. Silencing of microRNAs in vivo with `antagomirs`. Nature 2005, 438:685–689.
Baigude, H, Rana, TM. Interfering nanoparticles for silencing microRNAs. Methods Enzymol 2012, 509:339–353.
Mattes, J, Yang, M, Foster, PS. Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specific regulation of gene function? Am J Respir Cell Mol Biol 2007, 36:8–12.
Woodrow, KA, Cu, Y, Booth, CJ, Saucier‐Sawyer, JK, Wood, MJ, Saltzman, WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small‐interfering RNA. Nat Mater 2009, 8:526–533.
Zeng, P, Xu, Y, Zeng, C, Ren, H, Peng, M. Chitosan‐modified poly(D,L‐lactide‐co‐glycolide) nanospheres for plasmid DNA delivery and HBV gene‐silencing. Int J Pharm 2011, 415:259–266.
Du, J, Shi, QS, Sun, Y, Liu, PF, Zhu, MJ, Du, LF, Duan, YR. Enhanced delivery of monomethoxypoly(ethylene glycol)‐poly(lactic‐co‐glycolic acid)‐poly l‐lysine nanoparticles loading platelet‐derived growth factor BB small interfering RNA by ultrasound and/or microbubbles to rat retinal pigment epithelium cells. J Gene Med 2011, 13:312–323.
Du, J, Sun, Y, Shi, QS, Liu, PF, Zhu, MJ, Wang, CH, Du, LF, Duan, YR. Biodegradable nanoparticles of mPEG‐PLGA‐PLL triblock copolymers as novel non‐viral vectors for improving siRNA delivery and gene silencing. Int J Mol Sci 2012, 13:516–533.
Li, YH, Shi, QS, Du, J, Jin, LF, Du, LF, Liu, PF, Duan, YR. Targeted delivery of biodegradable nanoparticles with ultrasound‐targeted microbubble destruction‐mediated hVEGF‐siRNA transfection in human PC‐3 cells in vitro. Int J Mol Med 2013, 31:163–171.
Lu, ZX, Liu, LT, Qi, XR. Development of small interfering RNA delivery system using PEI‐PEG‐APRPG polymer for antiangiogenic vascular endothelial growth factor tumor‐targeted therapy. Int J Nanomed 2011, 6:1661–1673.
Dragomira Nikolova, DT. RNA interference—regulations and application in oncology. J Cancer Mol 2008, 4:67–77.
Rao, DD, Vorhies, JS, Senzer, N, Nemunaitis, J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009, 61:746–759.
Paddison, PJ, Caudy, AA, Bernstein, E, Hannon, GJ, Conklin, DS. Short hairpin RNAs (shRNAs) induce sequence‐specific silencing in mammalian cells. Genes Dev 2002, 16:948–958.
Check, E. A crucial test. Nat Med 2005, 11:243–244.
Wang, SL, Yao, HH, Qin, ZH. Strategies for short hairpin RNA delivery in cancer gene therapy. Exp Opin Biol Ther 2009, 9:1357–1368.
Zhang, C, Wang, YS, Wu, H, Zhang, ZX, Cai, Y, Hou, HY, Zhao, W, Yang, XM, Ma, JX. Inhibitory efficacy of hypoxia‐inducible factor 1α short hairpin RNA plasmid DNA‐loaded poly (D, L‐lactide‐co‐glycolide) nanoparticles on choroidal neovascularization in a laser‐induced rat model. Gene Ther 2010, 17:338–351.
Qazi, Y, Stagg, B, Singh, N, Singh, S, Zhang, X, Luo, L, Simonis, J, Kompella, UB, Ambati, BK. Nanoparticle‐mediated delivery of shRNA.VEGF‐a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci 2012, 53:2837–2844.
Yang, J, Xie, SX, Huang, Y, Ling, M, Liu, J, Ran, Y, Wang, Y, Thrasher, JB, Berkland, C, Li, B. Prostate‐targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine 2012, 7:1297–1309.
Huang, Z, Dong, L, Chen, J, Gao, F, Zhang, Z, Zhang, J. Low‐molecular weight chitosan/vascular endothelial growth factor short hairpin RNA for the treatment of hepatocellular carcinoma. Life Sci 2012, 91:1207–1215.
Yin, Q, Gao, Y, Zhang, Z, Zhang, P, Li, Y. Bioreducible poly (β‐amino esters)/shRNA complex nanoparticles for efficient RNA delivery. J Control Release 2011, 151:35–44.
Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795–803.
Kim, DH, Rossi, JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007, 8:173–184.
Whitehead, KA, Langer, R, Anderson, DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129–138.
Soman, P, Kelber, JA, Lee, JW, Wright, TN, Vecchio, KS, Klemke, RL, Chen, S. Cancer cell migration within 3D layer‐by‐layer microfabricated photocrosslinked PEG scaffolds with tunable stiffness. Biomaterials 2012, 33:7064–7070.
Su, WP, Cheng, FY, Shieh, DB, Yeh, CS, Su, WC. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomed 2012, 7:4269–4283.
Zhang, J, Lan, CQ, Post, M, Simard, B, Deslandes, Y, Hsieh, TH. Design of nanoparticles as drug carriers for cancer therapy. Cancer Genom Proteom 2006, 3:147–157.
Brewer, E, Coleman, J, Lowman, A. Emerging technologies of polymeric nanoparticles in cancer drug delivery. J Nanomater 2011, 2011:1–10.
Acharya, S, Sahoo, SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011, 63:170–183.
Hochwald, SN. Molecular‐targeted therapy for cancer and nanotechnology. Methods Mol Biol 2010, 624:11–23.
Bae, YH, Park, K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 2011, 153:198–205.
Farokhzad, OC, Jon, S, Khademhosseini, A, Tran, TN, Lavan, DA, Langer, R. Nanoparticle‐aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004, 64:7668–7672.
Dusinska, M, Magdolenova, Z, Fjellsbo, LM. Toxicological aspects for nanomaterial in humans. Methods Mol Biol 2013, 948:1–12.
Oberdorster, G, Oberdorster, E, Oberdorster, J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005, 113:823–839.
Semete, B, Booysen, L, Lemmer, Y, Kalombo, L, Katata, L, Verschoor, J, Swai, HS. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomed Nanotechnol Biol Med 2010, 6:662–671.
Devalapally, H, Shenoy, D, Little, S, Langer, R, Amiji, M. Poly(ethylene oxide)‐modified poly(β‐amino ester) nanoparticles as a pH‐sensitive system for tumor‐targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother Pharmacol 2006, 59:477–484.
Mura, S, Hillaireau, H, Nicolas, J, Le Droumaguet, B, Gueutin, C, Zanna, S, Tsapis, N, Fattal, E. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu‐3 cells. Int J Nanomed 2011, 6:2591–2605.
Yildirimer, L, Thanh, NT, Loizidou, M, Seifalian, AM. Toxicology and clinical potential of nanoparticles. Nano Today 2011, 6:585–607.